Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Cogent Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.
The source filing: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 8:21 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-205170
FAQ
- What is Cogent Biosciences, Inc.'s D&A?
- Cogent Biosciences, Inc. (COGT) reported D&A of $626K in Q1 2026.
- How has Cogent Biosciences, Inc.'s D&A changed year-over-year?
- Cogent Biosciences, Inc.'s D&A decreased by 2.2% year-over-year, from $640K to $626K.
- What is the long-term trend for Cogent Biosciences, Inc.'s D&A?
- Over 4 years (2021 to 2025), Cogent Biosciences, Inc.'s D&A has grown at a 104.4% compound annual growth rate (CAGR), from $147K to $2.56M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Cogent Biosciences, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude